As Biotechnology businesses, OHR Pharmaceutical Inc. (NASDAQ:OHRP) and InflaRx N.V. (NASDAQ:IFRX), are affected by contrast. This especially applies to their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|OHR Pharmaceutical Inc.||N/A||0.00||8.94M||-3.54||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|OHR Pharmaceutical Inc.||0.00%||-71.5%||-66.8%|
The Current Ratio and Quick Ratio of OHR Pharmaceutical Inc. are 5.4 and 5.4 respectively. Its competitor InflaRx N.V.’s Current Ratio is 20.4 and its Quick Ratio is 20.4. InflaRx N.V. can pay off short and long-term obligations better than OHR Pharmaceutical Inc.
OHR Pharmaceutical Inc. and InflaRx N.V. Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|OHR Pharmaceutical Inc.||0||0||0||0.00|
Meanwhile, InflaRx N.V.’s consensus target price is $6, while its potential upside is 94.81%.
Institutional & Insider Ownership
Roughly 13.4% of OHR Pharmaceutical Inc. shares are held by institutional investors while 62.1% of InflaRx N.V. are owned by institutional investors. Insiders held 8.89% of OHR Pharmaceutical Inc. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|OHR Pharmaceutical Inc.||-6.09%||13.42%||16.96%||-37.26%||-36.07%||52.33%|
For the past year OHR Pharmaceutical Inc. was more bullish than InflaRx N.V.
InflaRx N.V. beats OHR Pharmaceutical Inc. on 6 of the 7 factors.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.